Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South KoreaArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] baseline BNT BNT162b2 ChAdOx1 cohort study collected comparable conducted convalescent COVID-19 patients convalescent sera correlation COVID-19 COVID-19 pandemic COVID-19 vaccination cumulative Decreased Delta delta variant dose estimation explain groups HCW HCWs healthcare worker Heterologous highest homologous IQR Kinetics median Neutralizing neutralizing antibody Neutralizing antibody titer outbreak performed PRNT Protective protective immunity protocol SARS-CoV-2 sera serum sample significantly higher South Korea the mean vaccination Vaccine development variants of concern VoC VOCs was used wild type wild-type SARS-CoV-2 WT SARS-CoV-2 [DOI] 10.3389/fimmu.2022.968105 PMC 바로가기
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunityArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] age Antibody Response BNT162b2 children CoronaVac COVID-19 determine dose flow cytometry homologous Hong Kong humoral IgG IgG response Immunity immunodeficiency inactivated Inadequate inborn errors of immunity include intracellular cytokine staining Intradermal intramuscular mRNA vaccine neutralization nonrandomized of BNT162b2 omicron Patient patients receiving response S-RBD Safety SARS-CoV-2 antigen T cell response Two patient vaccination Vaccine Virus neutralization [DOI] 10.3389/fimmu.2022.982155 PMC 바로가기
The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 virusesArticle Published on 2022-09-202022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] 95% confidence interval addition Anti-RBD IgG B.1.1.529 B.1.351 B.1.617.2 Beta booster booster dose booster vaccination Booster vaccine breadth Cohort convalescent COVID-19 patient CoronaVac Critical cross-neutralization Delta dose examined highlight homologous immune response increase in less log magnitude neutralization neutralization breadth neutralization titer neutralize omicron positive proportion receiving recipient reduction reported Result SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus Significant the antibody response vaccination Vaccine variant variants wild-type [DOI] 10.3389/fimmu.2022.990071 PMC 바로가기
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trialArticle Published on 2022-09-122022-11-15 Journal: Nature Communications [Category] SARS, 진단, [키워드] 1:1 age Analysis antibody blinded BNT162b2 booster vaccination cellular immune responses ChAdOx1 nCoV-19 clinical trial COVID-19 COVID-19 vaccination determine dose Endpoint EudraCT Heterologous homologous Immunosuppressed immunosuppressed patients Impaired include mRNA mRNA vaccination mRNA vaccine mRNA-1273 multivariable logistic regression outcome Patient performed Randomized Randomized controlled trial receive reduced SARS-CoV-2 spike SARS-CoV-2-specific T-cell response secondary Serious Adverse Event Seroconversion seroconversion rate seroconvert significantly higher single center Support vaccination Vaccination strategy Vaccine vaccine group [DOI] 10.1038/s41467-022-33036-y PMC 바로가기
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinationsArticle Published on 2022-09-022022-11-16 Journal: Communications Biology [Category] SARS, 변종, [키워드] antibody Antibody Response booster dose Course COVID-19 COVID-19 patient cross-protection delta variant drastic reduction elicited ENhance evaluate Heterologous highest homologous Immunity mRNA vaccine Mutation natural infection neutralization capacity neutralize omicron Patient regimen replaced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus serum sample survivor susceptibility tested the spike protein vaccinated individual vaccination Vaccine vaccinee variant wild-type virus [DOI] 10.1038/s42003-022-03849-0 PMC 바로가기
Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter studyArticle Published on 2022-09-012022-11-15 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Acetate anti-CD20 antibody Asymptomatic B-cell Course Disease-modifying therapy expected fumarate group healthy healthy control Heterologous homologous humoral Humoral response immune response Interferon-beta mAb majority median Mild multicenter Multiple multiple sclerosis Patient patients Probability Protective reached receiving reduced reported revaccination SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection Seroconversion significantly significantly lower study enrollment therapy Third U/mL vaccination was measured while [DOI] 10.1016/j.msard.2022.104009 PMC 바로가기
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccinationArticle Published on 2022-09-012022-10-06 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] Anti-spike antibodies Antibody Response benefit BNT162b2 comparable develop dose evaluate event Heterologous homologous IMPROVE mRNA vaccination mRNA vaccine mRNA vaccines naïve Poisson regression reactogenicity recipient recipients remained SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion seroconvert seronegative solid organ transplant Tolerability Transplant vaccination Vaccine [DOI] 10.1111/ajt.17061 PMC 바로가기 [Article Type] Article
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimodArticle Published on 2022-09-012022-11-15 Journal: Journal of neurology, neurosurgery, and psychiatry [Category] COVID19(2023년), SARS, 진단, [키워드] absence Acetate Alter analysed antagonist approved Autoimmune diseases B cell B cells booster booster vaccinations CD4 Cellular immune response clinical neurology elicit elicited fumarate functional immune response healthy individual homologous humoral humoral immune response IgG Immune cell immunogenic immunology Infection Infectious diseases investigated lack Measures mRNA mRNA vaccination mRNA vaccine multiple sclerosis Neutralising activity Patient patients Peripheral blood prospective cohort study Protective receiving receptor Receptor binding reduced risk SARS-CoV-2 serum severe COVID-19 severe SARS-CoV-2 stability T cell T cell response T cell responses therapy these cell Treatment vaccination Vaccinations vaccine-specific antibodies [DOI] 10.1136/jnnp-2022-329395 PMC 바로가기
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protectionComirnaty® COVID-19 백신의 동종 3차 접종 후 요양원 거주자의 SARS-CoV-2 Omicron BA.1 변이형 돌발성 감염: 보호 상관 관계 찾기Observational Study Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료제, [키워드] anti-RBD Anti-spike anti-spike antibodies antibody blood levels booster dose both groups Breakthrough infection CD4 CD8 chemiluminescent immunoassay Comirnaty® COVID-19 vaccine comparable COVID-19 COVID-19 vaccine cytokine detectable dose evaluated female flow cytometry Frequency homologous immune parameter Immunological response in both groups individual level Infection intracellular cytokine staining investigated likelihood median median age Neutralization assay Neutralizing Neutralizing antibodies neutralizing antibody not correlated nursing home nursing home residents observational study omicron Omicron variant participant Peripheral blood predict Pseudotyped virus quantified reactive Receptor binding domain risk SARS-CoV-2 SARS-CoV-2 Omicron variant SARS-CoV-2 spike SARS-CoV-2-S spike spike-reactive T cells. subsequent symptomatic T cell T cells total antibody uninfected participant Vaccine variant were measured [DOI] 10.1002/jmv.27867 PMC 바로가기 [Article Type] Observational Study
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccinationArticle Published on 2022-09-012022-10-05 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] Administered Adverse Anti-RBD IgG AZD1222 binding BNT162b2 boost booster booster vaccination Booster vaccine cellular response COVID-19 COVID-19 vaccines domain dose elicited enrolled evade event Evidence healthy Heterologous heterologous booster highest homologous homologous or heterologous humoral Immunity Immunoglobulin individual individuals Messenger RNA mRNA mRNA-1273 Mutation NAb NAbs neutralization neutralizing antibody objective omicron overcome participant peaked persistence provided RBD reactogenicity reduction Result SARS-CoV-2 significantly T cell response T cells Total vaccination Vaccinations Vaccine vaccine dose Vaccines variant variants waning immunity [DOI] 10.1016/j.ijid.2022.07.038 [Article Type] Article